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Abstract 
Background 
Health services have failed to respond to the pressures of multimorbidity. There is a need for 
improved measures of multimorbidity for research, planning services and resource allocation. 
Methods 
Development (N=300,000) and validation (N=150,000) data samples were extracted from the UK 
Clinical Practice Research Database. We modelled the association between 37 morbidities and key 
outcomes (primary care consultations, unplanned hospitalization, mortality) at one and five years 
using Cox and zero-inflated negative binomial regression. A general-outcome multimorbidity score 
was constructed by averaging the standardised weights of the separate outcome scores. 
Performance was compared with the Charlson co-morbidity index. 
Results 
Models including all 37 conditions were acceptable predictors of GP consultations, hospitalisation 
and mortality at one-year (C-indices 0.732 [95% confidence interval 0.731-0.734], 0.742 [0.737-
0.747] and 0.912 [0.905-0.918] respectively, adjusted for age/gender). Reducing the models to the 
20 conditions which had the greatest combined prevalence/weight made little difference to the 
predictive value of the models (C-indices 0.727 [0.725-0.728], 0.738 [0.732-0.743] and 0.910 [0.904-
0.917] respectively). Prediction of outcomes at five years for the 20-condition model remained 
similar for consultations and mortality (C-indices 0.735 [0.734-0.736], 0.889 [0.885-0.892]) but 
performed less well for admissions (C-index 0.708 [0.705-0.712]). The general-outcome score 
performed similarly to the outcome-specific models. Models performed significantly better than 
those based on Charlson. 
Conclusions 
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This analysis provides several robust, simple-to-use multimorbidity scores, both tailored and not 
tailored to specific health outcomes. The scores will be valuable to those planning clinical services, 
policymakers allocating resources, and researchers seeking to account for the effect of 
multimorbidity.  
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Introduction 
Patients with multiple long-term health conditions are familiar to clinicians in generalist and 
specialist settings.1,2 Services and policies have failed to respond to the pressures multimorbidity 
places on primary and secondary care. These pressures are driven by the ageing population, by 
policies which promote rapid access over longer consultations and continuity of care, and by single 
disease guidelines and performance targets which lead to over-prescribing and fail to address the 
priorities of multimorbid individuals.3,4 
Several approaches have been used to quantify multimorbidity. Simple counts of conditions show a 
clear association with various outcomes, including primary care utilisation, unplanned 
hospitalisation, and death.5,6 Weighted approaches allow for differences in the strength of 
association between specific morbidities and a given outcome, such as the Charlson index which 
provides a composite morbidity score with condition weightings based on mortality.7 Although its 
performance has been shown to exceed a number of other metrics4, clinical practice has advanced 
considerably since its’ development in the 1980s and the high weightings of particular conditions has 
been questioned. A further problem with such indices is that weightings are generally based on a 
specific outcome such as mortality, and may not predict other outcomes. The lists of conditions are 
also problematic. A minimum list of 12 conditions has been proposed.8 However, a limited list may 
fail to capture important health problems, and comprehensive lists such as the Adjusted Clinical 
Groups (ACG) System may be challenging to implement. 
The aim of the current study was to develop and validate a transparent, simple measure of 
multimorbidity based on data from UK general practitioner records and weighted on different 
clinical outcomes, that could be used in future studies of multimorbidity and for resource allocation. 
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Methods 
Population and data sources 
A retrospective cohort study was undertaken using anonymous coded UK general practice (GP) 
electronic health record data from the Clinical Practice Research Datalink (CPRD).9 
We restricted our analysis to the 148 practices contributing data classified by CPRD as “up to 
standard” from 2010 to 2015, with primary care records linked to national data on mortality (Office 
for National Statistics, ONS)10, hospitalisation (Hospital Episode Statistics, HES)11 and socioeconomic 
deprivation (Index of Multiple Deprivation, IMD).12 To ensure independence of samples, practices 
were randomly sampled into one of three datasets (2:1:1). The development dataset included 
300,000 randomly-sampled adults aged ≥20 years registered on 1/1/2014 (study start), with data 
classified by CPRD as acceptable for use in research. The presence of morbidities was determined at 
an index date 12-months after the study start (1/1/2015), to ensure at least one year of registration 
and maximise recording of prevalent cases. Patient records were followed for one year after the 
index date (study end 31/12/2015). The first validation dataset included 150,000 patients with the 
same specification as the development dataset. A similar, second validation dataset of 150,000 
patients provided up to 5-year follow-up, as well as a 1-year asynchronous follow-up (study start 
1/1/2010; index date 1/1/2011; data available until 31/12/2015). The sample size was selected to 
limit the width of a 95% confidence interval for a condition with 2% prevalence to approximately 0.5 
on the log-odds scale for a dichotomous outcome such as mortality. Flow charts for the selection of 
practices and patients are presented in Appendix S1, with details of the time periods and dates of 
each dataset given in Appendix S2. 
Exposures 
Co-morbidities were defined by relevant Read codes and/or prescribing prior to the index date, 
based on a list of 37 long-term conditions as described by Cassell and colleagues, and adapted from 
work by Barnett and colleagues which is considered one of the definitive epidemiological studies of 
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multimorbidity (Appendix S3). 2, 13 The conditions were chosen and defined based on clinical expert 
consensus as those having a significant impact on patients. The current study and that of Cassell 
align closely, both aiming to develop better means of quantifying multimorbidity. An additional 
condition list was included for the Charlson index.14  The code lists used were subject to considerable 
clinical attention, and we thus consider all the comorbidities to have face-validity; previous studies 
of the CPRD dataset have shown the majority of long-term conditions to have positive predictive 
value in excess of 80%.15  Gender and age were included as covariates. 
Outcomes 
ONS data and HES admitted patient care data were used to determine the occurrence of death and 
unplanned (emergency) inpatient hospitalization respectively during the follow-up period. Number 
of primary care consultations was established from GP records of face-to-face (including telephone) 
clinical encounters; multiple encounters per day were counted as one consultation. 
Statistical analysis 
Morbidity scores were developed using three separate models, one for each outcome, in the 2015 
development dataset. Consultations were modelled using zero-inflated negative binomial 
regression, and mortality and unplanned hospitalisation using Cox regression. In addition to the 
extended scores containing all 37 conditions, we constructed a set of simplified primary scores 
including the most important 20 conditions. In addition, a general-outcome multimorbidity score 
was constructed by averaging the standardised weights of the three simple scores. Details of the 
statistical modelling (including data cleaning) are provided in Appendix S3. 
Performance of each of the three 37-condition and 20-condition outcome-specific scores, as well as 
the 20-condition general-outcome score, was independently evaluated at 1-year follow-up in the 
2015 (synchronous) dataset, as well as at 1-year and 5-years follow-up in the 2011 (asynchronous) 
dataset. We examined the performance of each score for predicting each of the three outcomes, 
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and additionally compared performance against the Charlson index. Model fit was assessed using 
Harrell’s C-index.  
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Results 
The characteristics of the different cohorts is shown in Table 1, and descriptive statistics for the 
multimorbidity scores are presented in Appendix S4. The development cohort had a mean age of 
50.7 years, with 23% and 6% aged over 65 years and 80 years respectively. 51% of patients were 
female.  The most socioeconomically deprived were under-represented. The mean (standard 
deviation) number of morbidities was 1.3 (1.7), with 31.7% of individuals having 2 or more recorded 
conditions. The commonest conditions (Table 2) were hypertension (19.2%), anxiety or depression 
(12.9%), painful condition (11.6%) and hearing loss (11.3%); the full list of disease prevalence and 
score weightings is provided in Appendix S5. In general, similar patterns of age, gender, 
socioeconomic deprivation and multimorbidity were observed across all cohorts (Table 1). 
In the development cohort, mean consultation rate was 5.9 per person-year, mortality 10.7 per 1000 
person-years, and unplanned admission rate 69.5 per 1000 person-years (Table 3). Similar figures 
were observed for the 2015 validation cohort. Mortality rates were similar for the 2011 validation 
cohort, although admission rates in particular were considerably lower in the 2011 cohorts, 
especially when based on 5-year follow-up. 93.7% of patients had complete follow-up in the 
development dataset, with similar numbers for the other 1-year follow-up validation groups; follow-
up was 75.1% complete at 5-years for the 2011 cohort. 
Consultation models 
The C-index for prediction of consultations in the 2015 validation dataset, using a model 
incorporating the 37-condition weighted multimorbidity score and adjusting for age and gender, was 
0.732 (95% confidence interval, 95% CI 0.731-0.734). Comparison of this model against other models 
is presented in Appendix S6, and model output presented in Appendix S7. Using the score directly, 
without additionally adjusting for age and gender resulted in poorer performance (C=0.702, 95% CI 
0.701-0.704). An adjusted model incorporating each condition as a binary variable performed only 
slightly better (C=0.737, 95% CI 0.736-0.739) than using the single weighted score. Performance was 
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only very slightly worse for predicting consultations over 1 year from 2011 (C=0.724, 95% CI 0.722-
0.725), and a little better for 5-year prediction (C=0.739, 95% CI 0.738-0.740). 
Unplanned admission models 
The C-index for prediction of unplanned admissions in the 2015 validation dataset, based on an 
adjusted 37-condition weighted score, was 0.742 (95% CI 0.737-0.747; Appendix S8). Model output 
is presented in Appendix S9. Performance was only marginally worse when age and gender were 
excluded (C=0.738, 95% CI 0.733-0.744), and almost identical to an adjusted model incorporating 
separate conditions (C=0.743, 95% CI 0.738-0.748). 1-year and 5-year performance using the 2011 
dataset was similar (C=0.739, 95% CI 0.733-0.744) and substantially worse (C=0.712, 0.709-0.715) 
respectively. 
Mortality models 
Prediction of mortality in the 2015 validation dataset, based on an adjusted score for all 37-
conditions weighted by age and gender, was excellent (C=0.912, 95% CI 0.905-0.918; Appendix S10). 
Model output is presented in Appendix S11. There was worse (albeit still very good) performance 
upon excluding age and gender (C=0.868, 95% CI 0.857-0.878). An adjusted model incorporating all 
37 conditions with age and gender separately performed slightly better (C=0.920, 95% CI 0.914-
0.926). Performance at both 1-year and 5-year in the 2011 dataset was only marginally worse 
(C=0.901, 95% CI 0.894-0.908 and C=0.890, 95% CI 0.886-0.894 respectively). 
Primary (20-condition) outcome-specific multimorbidity scores 
We constructed simplified primary versions of the scores based on the 20 most important 
conditions. Selection of conditions was based upon those conditions ranking highest in terms of 
average ranking of both prevalence and effect size. This selection of 20 conditions was considered 
clinically most relevant and associated with better model performance, in comparison to selection 
based on prevalence or effect size alone. Compared to the 37-condition score, model performance 
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was only marginally worse for each outcome (Table 4: consultations, C=0.727 (95% CI 0.725-0.728); 
admissions, C=0.738 (95% CI 0.732-0.743); mortality, C=0.910 (95% CI 0.904-0.917)). 
Comparison of performance for different outcomes 
A multimorbidity score may also be used to predict outcomes for which it was not originally 
designed. For example, a score weighted based on one particular outcome (e.g. mortality) used to 
predict a different outcome (e.g. admissions). Therefore we also examined performance for each of 
the different scores (i.e. mortality, admissions, consultations) not just against the corresponding 
outcome but for the alternative outcomes as well (Table 5). In general, all adjusted models predicted 
mortality well, with the admissions model performing best (C=0.913, 95% CI 0.906-0.919). The 
consultation and admission models each performed similarly in predicting the alternative outcome. 
However, the mortality model was notably worse at predicting either consultations (C=0.694, 95% CI 
0.692-0.696) or admissions (C=0.712, 95% CI 0.706-0.717). We also explored the correlation in 
multimorbidity scores at the person level (Table 6). In particular, this showed the weakest 
correlation between the consultation and mortality-based scores (0.777, 95% CI 0.775-0.779), and 
the strongest correlation between the admissions and consultation-based scores (0.947, 95% CI 
0.946-0.947). 
Primary general-outcome multimorbidity score 
A general (i.e. not outcome-specific) 20-condition score, based on the combined weights, had similar 
performance for each of the three outcomes as the outcome-specific models (Tables 4 and 5: 
consultations, C=0.723 (95% CI 0.722-0.725); admissions, C=0.735 (95% CI 0.729-0.740); mortality, 
C=0.913 (95% CI 0.907-0.920)), with a strong correlation between general-outcome and outcome-
specific scores (Table 6). 
Comparison against Charlson index 
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The Charlson index, adjusted for age and gender, performed less well than the primary (20-
condition) outcome-specific and general-outcome models, for all three outcomes (Table 4), although 
the performance difference for mortality was minimal (Appendix S12). Of note, when no adjustment 
for age or gender was carried out, performance dropped relatively more with Charlson across all 
three outcomes, particularly for mortality. 
Model calibration 
Calibration plots are presented in Appendix S13. These show reasonable calibration for mortality and 
emergency admissions, although consultation rates are underestimated (to be expected as persons 
with no long-term conditions are still likely to consult their GP at times).   
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Discussion 
This study has developed several robust, outcome-specific multimorbidity scores, with acceptable 
predictive validity for primary care utilisation, unplanned hospitalisation and mortality. The primary 
(simplified) models perform nearly as well as the more complex extended ones, and the general-
outcome multimorbidity score performs similarly across all outcomes and over time. The scores 
outperform the widely used Charlson index across all outcomes. Performance is best for mortality, 
particularly following adjustment for age and gender, and least good for consultations. 
Policy and research relevance 
These scores have benefits over commonly used existing measures, including weightings for several 
outcomes and a pragmatic balance of number and choice of conditions (which in the UK align with 
those recently proposed for practice multimorbidity registries.16 A person’s score can be calculated 
by summing the weights of their individual conditions, according to the outcome considered most 
appropriate for the given context. 
Multimorbidity scores offer a means of identifying those patients in the population who are most 
likely to benefit from a tailored approach to care, helping clinicians to prioritise their efforts 
accordingly,17 but are unlikely to have a direct role in individual patient care. The score we have 
described specifically quantifies multimorbidity, as opposed to focusing on the identification of a 
specific priority problem such as unplanned admissions (e.g. QAdmissions18) or frailty (e.g. electronic 
Frailty Index, eFI19), and as such may be more relevant to optimising the delivery of care for those 
with multimorbidity. Morbidity scores can also inform health policy decision making, including 
resource allocation. Patient case-mix, as measured using the comprehensive ACG system, has been 
shown to explain most of the variance in patient costs in a study of Swedish primary care.20 
However, in UK primary care, the funding allocation (Carr-Hill) formula does not account for patient 
morbidity directly.21 Scores developed via a transparent process, with “real world” contemporary 
data and weightings incorporating a range of key outcomes, should help policy-makers and clinicians 
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understand and support their use for priority setting purposes. In addition, multimorbidity scores 
provide an opportunity to capture clinical complexity and to identify what matters most in general 
practice, for example by moving away from the UK’s current single-condition based payment-for-
performance QOF incentivisation system.22 
Finally, having a robust method of quantifying multimorbidity facilitates research, including 
descriptive epidemiological analysis and matching individuals on morbidity status. In particular, 
multimorbidity scores can be added to routine datasets to evaluate how the response to many 
clinical and health service interventions varies with morbidity. Future work should also be 
undertaken to explore the utility of the scores in practice, as well as better understanding how the 
scores are associated with other important clinical outcomes such as function, quality of life and 
experience of care. 
Strengths and limitations 
The study has several important strengths, utilising contemporary data from a large, representative 
primary care population, and including a range of pertinent long-term clinical conditions. 
Performance was evaluated for different years and follow-up periods, increasing confidence in 
external generalizability and performance over time. There are also important limitations. 
Interpreting C-index values involves a measure of judgement in terms of what constitutes an 
important threshold. Nevertheless, our conclusions are based on conventional standards, and in 
particular there is an order of magnitude improvement (2-11%) over Charlson. Diagnostic coding in 
medical records is undertaken for clinical rather than research purposes, and is subject to 
misclassification or missingness.15 However, this also means the scores’ performance reflects that 
expected in the real world. We used established UK Read coding rather than the newer international 
SNOMED-CT being introduced currently in UK practice. Nevertheless, these can be readily mapped 
to one another, and most conditions are captured by a small subset of codes so we believe this is 
unlikely to have significantly impacted upon findings. Furthermore, although the models are based 
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on UK data, there is no reason to suspect that the findings do not generalize to other non-UK 
settings; similar scores such as Charlson have demonstrated international applicability. We have only 
conducted a comparison of performance against Charlson, so are unable to claim superiority or 
equivalence to alternative metrics. It is also possible to question the list of conditions. Although 
based on well-established previous work, two morbidities are particularly noteworthy. Firstly, the 
use of chronic pain rather than specific musculoskeletal conditions: the former is both common and 
clinically meaningful, and has the advantage of capturing the latter whilst more-readily 
distinguishing chronic from self-limiting conditions. Secondly, constipation might also be viewed as 
anomalous, but has a similar prevalence to other important conditions,2 is common in older people, 
and can significantly impact quality of life.  A further issue was our omission of several important 
predictors from the models (e.g. previous healthcare utilization). However, the aim of the study was 
not to develop the best risk prediction tools, but rather an optimal approach to describe or adjust 
for the general health status of individuals in health services and outcomes research. In addition, 
although we aimed to create a simpler score by minimising the number of conditions requiring 
recorded in practice, we elected not to simplify the weightings (cf. Charlson index) as these will most 
likely be implemented using electronic systems. A further advantage that the weightings are easily 
interpreted in terms of predicting outcomes on a natural scale. Finally, the impact of newly 
diagnosed co-morbidities on healthcare utilisation and mortality is likely to be much higher than 
longer-term health conditions; further work is required to examine the impact of timing of diagnoses 
on outcomes.   
Conclusions 
In conclusion, we have described the development of several robust, simple-to-use, multimorbidity 
scores, both tailored and not tailored to specific health and health service outcomes. These scores 
have the potential to be of considerable value for policy development and clinical priority setting, 
providing a clinically relevant, pragmatic, transparent, and methodologically easy-to-implement 
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means of optimising the delivery of healthcare to an ageing and increasingly multimorbid 
population. 
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Table 1 
Characteristics of the 3 samples used. 
 
Development 
dataset (2015) 
Validation 
dataset (2015) 
Validation 
dataset (2011) 
Gender    
% male 48.9 49.4 49.2 
% female 51.1 50.6 50.8 
Age at index date    
Mean (SD), years 50.7 (17.6) 51.0 (17.8) 50.1 (17.3) 
Range, years 21-95 21-95 21-95 
% over 65 22.7 23.8 20.6 
% over 80 5.8 6.0 5.1 
Deprivation quintiles (IMD2010), %    
1 (least deprived) 25.9 29.8 20.3 
2 24.5 19.3 20.3 
3 19.1 17.5 20.8 
4 16.6 18.0 22.6 
5 (most deprived) 13.9 15.4 16.0 
Multimorbidity    
Mean (SD), number of conditions 1.3 (1.7) 1.3 (1.8) 1.2 (1.7) 
Range, number of conditions 0-15 0-15 0-15 
% 0 conditions  45.0 43.3 46.9 
% 1 condition 23.3 23.5 23.4 
% 2 or more conditions 31.7 33.2 29.7 
SD, standard deviation; IMD, index of multiple deprivation 
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Table 2 
Prevalence and weights1 for the 20 conditions in the multimorbidity scores. 
 Prevalence2 
Weight for 
consultations3 
Weight for 
mortality4 
Weight for 
emergency 
admissions4 
General-
outcome 
weight5 
Hypertension 19.24 0.66 -2.09 10.76 0.08 
Anxiety/Depression 12.85 2.12 7.04 46.61 0.50 
Painful condition 11.63 3.43 16.46 84.93 0.92 
Hearing loss 11.27 1.04 -3.94 8.93 0.09 
Irritable bowel syndrome 7.61 1.82 -1.33 8.55 0.21 
Asthma  7.20 1.32 -2.73 22.78 0.19 
Diabetes 6.58 3.77 10.23 55.33 0.75 
Coronary heart disease 4.79 1.49 4.22 70.87 0.49 
Chronic kidney disease 4.50 0.98 16.61 52.13 0.53 
Atrial fibrillation 2.72 5.94 22.14 105.21 1.34 
Constipation  2.67 3.42 35.42 72.73 1.12 
Stroke & TIA 2.55 1.54 20.63 90.84 0.80 
COPD 2.46 3.43 42.50 134.51 1.46 
Connective tissue disorder 2.33 3.10 -0.39 28.87 0.43 
Cancer  2.15 2.58 62.00 104.80 1.53 
Alcohol problems 1.60 0.97 12.72 93.59 0.65 
Heart failure 1.04 2.90 43.47 73.20 1.18 
Dementia 1.02 1.81 124.42 156.90 2.50 
Psychosis/bipolar disorder 0.98 2.24 7.20 77.28 0.64 
Epilepsy  0.97 2.13 18.26 113.42 0.92 
TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease 
1. Negative weights can be interpreted as reflecting a negative association with the outcome of 
interest after controlling for other conditions 
2. Based on development dataset 
3. Per person-year 
4. Per 1,000 person-years 
5. Unit change associated a 1 standard deviation change in each of the three outcomes 
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Table 3 
Descriptive statistics for number of consultations, emergency hospital admissions, mortality and time 
of follow up in each cohort.  
 
 Development 
dataset 
Validation datasets 
 2015, 1-year 
follow-up 
2015, 1-year 
follow-up 
2011, 1-year 
follow-up 
2011, 5-year 
follow-up 
Number of consultations     
Consultation rate (per person-year) 5.92 5.84 5.52 5.68 
Mean N events in FU (SD) 5.7 (7.5) 5.6 (7.1) 5.3 (6.4) 24.5 (26.5) 
Range 0-162 0-237 0-110 0-493 
% zero consultations  21.9 21.3 20.3 8.7 
Mortality     
Number of deaths in FU 3,106 1,558 1,505 7,087 
Mortality rate  
(per 1,000 person-years) 
10.7 10.7 10.4 11.0 
Emergency admissions     
Number of first events in FU 19,509 10,045 8,878 30,075 
Rate (per 1,000 person-years) 69.5 71.6 63.1 51.8 
Follow-up time     
Mean (years per patient) 0.968 0.967 0.967 4.3 
N (%) patients with complete follow-up 281,150 (93.7) 140,353 (93.6) 140,325 (93.6) 112,586 (75.1) 
FU, follow-up; SD, standard deviation 
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Table 4 
Performance (C-index) of the 3 outcome-specific and general-outcome primary (20-condition) scores 
on two validation datasets: the 2015 dataset with up 1 year of follow-up and the 2011 dataset with 
up to 5 years of follow-up. Comparison against the Charlson score is provided. 95% confidence 
intervals shown in parentheses. 
 Scores adjusted by age and gender Unadjusted scores 
 Cambridge 
outcome-
specific 
score 
Cambridge 
general-
outcome 
score1 
Charlson 
score 
Cambridge 
outcome-
specific 
score 
Cambridge 
general-
outcome 
score 
Charlson 
score 
Consultations       
2015 1 year  0.727 
(0.725-0.728) 
0.723 
(0.722-0.725) 
0.691 
(0.690-0.693) 
0.692 
(0.691-0.694) 
0.690 
(0.689-0.691) 
0.605 
(0.603-0.606) 
2011 5 years 0.735 
(0.734-0.736) 
0.729 
(0.728-0.730) 
0.709 
(0.708-0.711) 
0.669 
(0.668-0.671) 
0.667 
(0.665-0.668) 
0.585 
(0.583-0.586) 
Mortality       
2015 1 year  0.910 
(0.904-0.917) 
0.913 
(0.907-0.920) 
0.907 
(0.900-0.914) 
0.868 
(0.857-0.879) 
0.880 
(0.872-0.889) 
0.804 
(0.792-0.815) 
2011 5 years 0.889 
(0.885-0.892) 
0.891 
(0.887-0.894) 
0.887 
(0.883-0.890) 
0.795 
(0.788-0.801) 
0.824 
(0.819-0.830) 
0.742 
(0.736-0.748) 
Emergency 
admissions 
      
2015 1 year  0.738 
(0.732-0.743) 
0.735 
(0.729-0.740) 
0.703 
(0.697-0.709) 
0.733 
(0.728-0.739) 
0.731 
(0.726-0.737) 
0.660 
(0.656-0.664) 
2011 5 years 0.708 
(0.705-0.712) 
0.706 
(0.703-0.709) 
0.683 
(0.680-0.686) 
0.694 
(0.691-0.698) 
0.692 
(0.689-0.695) 
0.623 
(0.621-0.625) 
1. The general-outcome score was constructed by averaging the standardised weights of the three 
simple scores.   
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Table 5 
Performance (C-index) of each primary score on all other outcomes. Performance was assessed in the 
2015 1-year follow-up sample including adjustment for age and gender. 95% confidence intervals 
shown in parentheses. 
 
How does the score for… 
N 
consultations 
Mortality 
Emergency 
admissions 
General-
outcome 
…perform on 
the outcome… 
N consultations 
0.727 
(0.725-0.728) 
0.694 
(0.692-0.696) 
0.723 
(0.722-0.725) 
0.723 
(0.722-0.725) 
Mortality 0.906 
(0.900-0.913) 
0.910 
(0.904-0.917) 
0.913 
(0.906-0.919) 
0.913 
(0.907-0.920) 
Emergency 
admissions 
0.735 
(0.729-0.740) 
0.712 
(0.706-0.717) 
0.738 
(0.732-0.743) 
0.735 
(0.729-0.740) 
 
 
 
 
 
Table 6 
Correlation* of the four primary scores at the person level. 95% confidence intervals shown in 
parentheses. 
 
 
N 
consultation
s 
Mortality 
Emergency 
admissions 
General-
outcome 
N consultations 1    
Mortality 0.777 
(0.775-0.779) 1  
 
Emergency admissions 0.947 
(0.946-0.947) 
0.889 
(0.888-0.890) 1 
 
General-outcome 0.950 
(0.950-0.951) 
0.929 
(0.929-0.930) 
0.989 
(0.988-0.989) 
1 
 
* Weights for each patient summed, and the within-individual Pearson correlation calculated 
between different scores. Results correspond to first validation sample.
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